CSRxP: PERA WOULD FURTHER ENABLE BIG PHARMA’S PATENT ABUSE THAT KEEPS PRESCRIPTION DRUG PRICES HIGH
Oct 7, 2025
Senate Judiciary Lawmakers Should Reject Big Pharma-Backed Proposal and… Read More
© 2026 CSRXP- All Rights Reserved
Updates
SECOND OPINION: BIG PHARMA’S RHETORIC OF DEFLECTION DOESN’T ADDRESS CAUSE OF HIGH PRESCRIPTION DRUG PRICES
Oct 6, 2025
PhRMA Continues to Dodge Responsibility for Egregious Pricing Practices and… Read More
THEY SAID IT!: LAWMAKERS HIGHLIGHT CRITICAL ROLE OF COMPETITION TO LOWER PRESCRIPTION DRUG PRICES IN MARKUP TO ADVANCE Q1/Q2 REFORMS
Sep 24, 2025
U.S. House Committee on Energy and Commerce Advances Bipartisan… Read More
DOSE OF REALITY: BIG PHARMA’S QUICK DELISTING OF MORE THAN 40 SHAM PATENTS HIGHLIGHTS SCALE OF PATENT THICKETS ON TOP MONEY-MAKERS
Sep 18, 2025
Analysis Finds Brand Name Drug Companies Declined to Even Attempt a Defense of… Read More
THEY SAID IT!: FDA COMMISSIONER: BIG PHARMA’S BILLIONS OF DOLLARS SPENT ON DTC ADVERTISING “WOULD BE BETTER SPENT ON LOWERING DRUG PRICES”
Sep 17, 2025
Makary Highlights and Adds to Momentum “Across the Political Spectrum” to… Read More
U.S. HOUSE COMMITTEE SHOULD ADVANCE Q1/Q2 REFORMS TO PROMOTE GREATER COMPETITION AND HELP LOWER PRESCRIPTION DRUG PRICES
Sep 17, 2025
Lawmakers Should Advance Bipartisan, Market-Based Solution to Crack Down on… Read More
DOSE OF REALITY: GENERIC AND BIOSIMILAR COMPETITION GENERATES SIGNIFICANT SAVINGS FOR PATIENTS AND THE U.S. HEALTH CARE SYSTEM
Sep 10, 2025
Report Underscores How Competition Lowers Prescription Drug Prices by… Read More
DOSE OF REALITY: STUDY FINDS BIG PHARMA’S PATENT THICKETS ON JUST FOUR BRAND NAME DRUGS COST MORE THAN $3.5 BILLION IN TWO YEARS
Sep 3, 2025
Patent Abuse Blocked Competition From More Affordable Alternatives For Periods… Read More
DOSE OF REALITY: BIG PHARMA’S PRICES FOR COSTLIEST 2025 MEDICATIONS OUTPACE FAIR PRICE ESTIMATES BASED ON CLINICAL VALUE
Aug 14, 2025
Highest Priced Brand Name Treatments Showcase Big Pharma’s Rising Launch… Read More
BIG PHARMA EARNINGS WATCH: GILEAD AND ELI LILLY
Aug 11, 2025
Gilead and Eli Lilly Latest Brand Name Drug Companies to Hike Prices… Read More
BIG PHARMA EARNINGS WATCH: AMGEN AND PFIZER
Aug 6, 2025
Amgen and Pfizer Bring in Billions of Revenue in Q2 Following Continued Price… Read More
THEY SAID IT! U.S. SENATE EXPERTS HIGHLIGHT BIPARTISAN, MARKET-BASED SOLUTIONS TO HOLD BIG PHARMA ACCOUNTABLE FOR PATENT ABUSE, BOOST COMPETITION TO LOWER DRUG PRICES
Aug 6, 2025
Joint DOJ-FTC Listening Session Focuses on Solutions to Foster Greater… Read More